Senseera

Senseera develops liquid biopsy blood tests for cancer diagnosis using its proprietary cfChIP-seq technology that detects cell-free chromatin tissue to identify patient-specific gene expression. Starting with just 1mL of plasma, the platform captures and sequences active chromatin, profiling over 1 million genomic features per sample to generate high-resolution gene expression biomarkers. Senseera's pipeline includes liver transplant rejection, MASH, and liver cancer diagnostics. Founded in 2020 and headquartered in Jerusalem, Israel, the company has raised approximately $7.1M in seed funding led by Lightspeed Venture Partners. Senseera differentiates itself through its AI-driven chromatin liquid biopsy platform that uncovers the molecular state of cells to inform disease biology and guide treatment decisions. The technology enables non-invasive insights across precision oncology, cell therapy, metabolic disease, and immune disease, enhancing every step of drug development from target selection to treatment monitoring.